GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Reunion Neuroscience Inc (TSX:REUN) » Definitions » ROA %

Reunion Neuroscience (TSX:REUN) ROA % : -78.28% (As of Mar. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Reunion Neuroscience ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Reunion Neuroscience's annualized Net Income for the quarter that ended in Mar. 2023 was C$-25.97 Mil. Reunion Neuroscience's average Total Assets over the quarter that ended in Mar. 2023 was C$33.17 Mil. Therefore, Reunion Neuroscience's annualized ROA % for the quarter that ended in Mar. 2023 was -78.28%.

The historical rank and industry rank for Reunion Neuroscience's ROA % or its related term are showing as below:

TSX:REUN's ROA % is not ranked *
in the Biotechnology industry.
Industry Median: -35.41
* Ranked among companies with meaningful ROA % only.

Reunion Neuroscience ROA % Historical Data

The historical data trend for Reunion Neuroscience's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Reunion Neuroscience ROA % Chart

Reunion Neuroscience Annual Data
Trend Mar20 Mar21 Mar22 Mar23
ROA %
-20.96 -33.27 -47.85 -73.54

Reunion Neuroscience Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -53.36 -56.60 -97.68 -124.07 -78.28

Competitive Comparison of Reunion Neuroscience's ROA %

For the Biotechnology subindustry, Reunion Neuroscience's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Reunion Neuroscience's ROA % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Reunion Neuroscience's ROA % distribution charts can be found below:

* The bar in red indicates where Reunion Neuroscience's ROA % falls into.



Reunion Neuroscience ROA % Calculation

Reunion Neuroscience's annualized ROA % for the fiscal year that ended in Mar. 2023 is calculated as:

ROA %=Net Income (A: Mar. 2023 )/( (Total Assets (A: Mar. 2022 )+Total Assets (A: Mar. 2023 ))/ count )
=-48.493/( (102.136+29.74)/ 2 )
=-48.493/65.938
=-73.54 %

Reunion Neuroscience's annualized ROA % for the quarter that ended in Mar. 2023 is calculated as:

ROA %=Net Income (Q: Mar. 2023 )/( (Total Assets (Q: Dec. 2022 )+Total Assets (Q: Mar. 2023 ))/ count )
=-25.968/( (36.604+29.74)/ 2 )
=-25.968/33.172
=-78.28 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2023) net income data. ROA % is displayed in the 30-year financial page.


Reunion Neuroscience  (TSX:REUN) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Mar. 2023 )
=Net Income/Total Assets
=-25.968/33.172
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-25.968 / 0)*(0 / 33.172)
=Net Margin %*Asset Turnover
=N/A %*0
=-78.28 %

Note: The Net Income data used here is four times the quarterly (Mar. 2023) net income data. The Revenue data used here is four times the quarterly (Mar. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Reunion Neuroscience ROA % Related Terms

Thank you for viewing the detailed overview of Reunion Neuroscience's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Reunion Neuroscience (TSX:REUN) Business Description

Traded in Other Exchanges
N/A
Address
30 Duncan Street, Lower North Suite, Toronto, ON, CAN, M5V 2C3
Reunion Neuroscience Inc is engaged in novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company's asset, RE-104 (previously known as FT-104), is a proprietary, novel psychedelic drug being developed for post-partum and treatment-resistant depression as a potential fast-acting antidepressant with durable efficacy.